Comparison between Vancomycin and Fidaxomicin in treatment ofCDI
DOI:
https://doi.org/10.61173/4k6fjx30Keywords:
Clostridium difficile infection, Clostridium difficile-associated diarrhea, epidemiology, antibiotics, Vancomycin, FidaxomicinAbstract
Clostridium difficile infection (CDI) has become more and more prevalent worldwide, requiring more attention from
people to treat this infection. In this work, the epidemiology of Clostridium difficile infection in the world and China is
demonstrated, which can contribute to a better understanding of the way of infection and patients’ conditions of CDI and
look for possible methods or policies to help prevent the spread of this disease. On the other hand, there is a growing
demand for more reliable and efficient antibiotic treatments for CDI, of which fidaxomicin and vancomycin are regarded
as the most common. This work aims to compare the chemical structures, action mechanisms, and cost-effectiveness of
fidaxomicin and vancomycin to assist choices between two antibiotics for CDI patients and healthcare workers.
References
[1] Ma, Jimmy, and Erik Dubberke. “Current Management [9] Nelson, Richard L, et al. “Antibiotic Treatment for of Clostridioides (Clostridium) Difficile Infection in Adults: Clostridium Difficile-Associated Diarrhoea in Adults.” Cochrane A Summary of Recommendations from the 2017 IDSA/ Database of Systematic Reviews, vol. 2017, no. 3, 2017, https:// Shea Clinical Practice Guideline.” Polish Archives of Internal doi.org/10.1002/14651858.cd004610.pub5. Medicine, 2018, https://doi.org/10.20452/pamw.4377. [10] Okano, Akinori, et al. “Total Syntheses of Vancomycin-
[2] Finn, Elaine, et al. “Burden of Clostridioides Difficile Related Glycopeptide Antibiotics and Key Analogues.” Infection (CDI) - A Systematic Review of the Epidemiology of Chemical Reviews, vol. 117, no. 18, 2017, pp. 11952–11993., Primary and Recurrent CDI.” BMC Infectious Diseases, vol. 21, https://doi.org/10.1021/acs.chemrev.6b00820. no. 1, 2021, https://doi.org/10.1186/s12879-021-06147-y. [11] Vaishnavi, Chetana. “Fidaxomicin - the New Drug
[3] Finn, Elaine, et al. “Burden of Clostridioides Difficile for Clostridium Difficile Infection.” Indian Journal of Infection (CDI) - A Systematic Review of the Epidemiology of Medical Research, vol. 141, no. 4, 2015, p. 398., https://doi. Primary and Recurrent CDI.” BMC Infectious Diseases, vol. 21, org/10.4103/0971-5916.159251. no. 1, 2021, https://doi.org/10.1186/s12879-021-06147-y. [12] Skinner, Andrew M, et al. “Fidaxomicin for the Treatment
[4] Blocker, O, et al. “Clostridium Difficile-Associated of Clostridioides Difficile in Children.” Future Microbiology, Diarrhoea in Primary Joint Arthroplasty in Aneurin Bevan vol. 15, no. 11, 2020, pp. 967–979., https://doi.org/10.2217/fmb- University Health Board South.” The Annals of The Royal 2020-0104. College of Surgeons of England, vol. 98, no. 03, 2016, pp. 222– [13] Artsimovitch, Irina, et al. “Fidaxomicin Is an Inhibitor of 225., https://doi.org/10.1308/rcsann.2016.0066. the Initiation of Bacterial RNA Synthesis.” Clinical Infectious
[5] Ma, Jimmy, and Erik Dubberke. “Current Management Diseases, vol. 55, no. suppl_2, 2012, https://doi.org/10.1093/cid/ of Clostridioides (Clostridium) Difficile Infection in Adults: cis358. A Summary of Recommendations from the 2017 IDSA/ [14] Jiang, Yiling, et al. “Budget Impact Analysis of Fidaxomicin Shea Clinical Practice Guideline.” Polish Archives of Internal versus Vancomycin for the Treatment of Clostridioides Difficile Medicine, 2018, https://doi.org/10.20452/pamw.4377. Infection in the United States.” Infectious Diseases and Therapy,
[6] Dai, Wei, et al. “Characteristics of Clostridium Difficile vol. 11, no. 1, 2021, pp. 111–126., https://doi.org/10.1007/ Isolates and the Burden of Hospital-Acquired Clostridium s40121-021-00480-0. Difficile Infection in a Tertiary Teaching Hospital in Chongqing, [15] Gallagher, Jason C., et al. “Clinical and Economic Benefits Southwest China.” BMC Infectious Diseases, vol. 20, no. 1, of Fidaxomicin Compared to Vancomycin for Clostridium 2020, https://doi.org/10.1186/s12879-020-05014-6. Difficile Infection.” Antimicrobial Agents and Chemotherapy,
[7] Cui, Yingchao, et al. “Risk Factors for Clostridioides vol. 59, no. 11, 2015, pp. 7007–7010., https://doi.org/10.1128/ Difficile Infection and Colonization among Patients Admitted aac.00939-15.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
